Agency Prescription Skincare: What the Platform Gets Right and Where It Falls Short for Women

What Agency Actually Is (and What It Replaced)

Agency is a prescription skincare telehealth platform that evolved from the model Curology pioneered: fill out an intake form, upload photos, get a licensed prescriber to build you a custom topical blend, and receive it by mail every month. The brand name "Agency" reflects a repositioning toward a broader adult demographic, though the clinical infrastructure is similar to what Curology still operates as a separate consumer brand.

The distinction matters for you as a patient. Curology and Agency share overlapping formulary options but serve slightly different audiences, with Agency leaning toward adult women dealing with post-adolescent acne, hyperpigmentation, and skin texture. That audience skews toward exactly the life stages where hormonal context is most consequential: the reproductive years, perimenopause, and the postpartum window.

The platform is legitimate in the sense that it employs licensed prescribers, ships FDA-regulated prescription drugs, and has published real-world outcomes data. Whether it is the right platform for you depends on which problem your skin is actually reflecting.

The Model Itself: How Prescribing Works

A new patient completes a photo-based skin intake, answers questions about current products and skin concerns, and is matched with a prescriber (typically a nurse practitioner or physician assistant, in some states a physician). A custom topical formula is compounded or dispensed from an FDA-registered pharmacy. The formula is adjusted over time based on follow-up check-ins, which are asynchronous in most cases.

The clinical strength of this model is speed and access. Women who cannot get a dermatology appointment for four months can have a tretinoin prescription in 48 hours. That is a genuine benefit, especially for the roughly 50 million Americans affected by acne, the majority of whom are women in their twenties and thirties.

The clinical weakness is what the intake form does not ask.

The Hormonal Context Gap: What the Skin Intake Misses

Hormones drive most acne in adult women. This is not a contested statement. The American Academy of Dermatology recognizes hormonal acne as a distinct clinical entity that responds differently to topicals than adolescent comedonal acne does. For a platform treating primarily adult women, the absence of a structured hormonal intake is a meaningful clinical omission.

Agency's intake form asks about your skin type, current products, and skin goals. It does not, in its standard workflow, ask:

• Where you are in your menstrual cycle when your breakouts peak
• Whether you have been diagnosed with PCOS or endometriosis
• Whether you are perimenopausal or recently postpartum
• Whether you are on hormonal contraception, and if so, which type
• Whether you have noticed hair thinning alongside acne (a marker of androgen excess)

Each of those questions changes the clinical picture substantially.

PCOS and Androgen-Driven Acne

Polycystic ovary syndrome affects approximately 8 to 13 percent of reproductive-age women and is one of the most common causes of persistent adult acne. The acne in PCOS is driven by elevated androgens, which increase sebum production at the follicular level. A topical retinoid will reduce comedone formation and accelerate cell turnover, and that genuinely helps. But it addresses the downstream effect, not the cause.

Women with PCOS-driven acne often achieve better long-term control with combined oral contraceptives containing anti-androgenic progestins (such as drospirenone or norgestimate), or with spironolactone, an oral aldosterone antagonist that the Journal of the American Academy of Dermatology has supported as first-line for hormonal acne in adult women. Agency's current model does not prescribe oral medications. If your acne is the visible signal of an androgen disorder, a topical-only approach is treating the surface of a systemic problem.

Perimenopause and the Changing Skin Envelope

Perimenopause typically begins in the mid-to-late forties, though for some women it starts in the late thirties. Estrogen decline changes skin at a structural level: collagen loss accelerates, barrier function decreases, and the androgen-to-estrogen ratio shifts so that relative androgen excess can appear even as total androgens decline. The result for many women is a paradox of acne, dryness, and new sensitivity occurring simultaneously.

The Menopause Society (formerly NAMS) notes that skin changes in menopause are driven by estrogen loss, with collagen declining approximately 30 percent in the first five years after menopause. A tretinoin formulation can slow some of that collagen loss. That part of Agency's value proposition is evidence-supported. But a perimenopausal woman whose acne is appearing for the first time in her mid-forties deserves a conversation about whether her hormonal status should be evaluated, not just her pore size.

Postpartum Skin: A High-Stakes Window

The postpartum period is one of the most hormonally volatile windows of a woman's life. Estrogen and progesterone crash within 24 to 48 hours of delivery. Prolactin rises in breastfeeding women. Thyroid autoimmunity can activate. Postpartum acne, melasma, and hair shedding are common, and they often drive women toward skincare solutions at exactly the moment when drug safety relative to lactation needs to be front of mind.

Agency does not have a documented postpartum intake pathway that screens for lactation status before prescribing. This is a safety gap, and the next section covers it in full.

Pregnancy, Lactation, and Contraception: The Required Safety Review

This section applies to any woman who is pregnant, breastfeeding, trying to conceive, or using Agency formulas while on contraception that might fail.

Tretinoin in Pregnancy: Contraindicated

Tretinoin (all-trans retinoic acid) is a retinoid. Oral retinoids are teratogenic. The topical form has lower systemic absorption than oral isotretinoin, but systemic absorption does occur: studies have measured detectable plasma tretinoin levels after topical application, and although absorption is substantially lower than oral routes, the teratogenic risk of the retinoid class means that tretinoin is contraindicated in pregnancy.

The FDA classifies topical tretinoin as Pregnancy Category C based on embryotoxicity and teratogenicity observed in animal studies, with inadequate human controlled trials. In practice, most dermatologists and OB-GYNs advise stopping topical tretinoin as soon as pregnancy is confirmed or planned. ACOG reinforces avoidance of all retinoids in pregnancy.

If you are using Agency and become pregnant, stop the tretinoin-containing formula immediately and contact your OB-GYN.

Tretinoin While Breastfeeding

Human data on topical tretinoin in lactation is sparse. Systemic levels after topical application are low, but no adequate studies have measured breast-milk transfer in breastfeeding women. LactMed, the NIH's drug-and-lactation database, classifies topical tretinoin as having insufficient data and suggests alternatives should be considered during breastfeeding. Most cautious clinicians advise pausing tretinoin while breastfeeding, particularly in the newborn period.

Azelaic Acid in Pregnancy and Lactation

Azelaic acid is a dicarboxylic acid with anti-inflammatory and tyrosinase-inhibiting properties. It is commonly used for acne and hyperpigmentation and is present in some Agency formulas. Azelaic acid is generally considered compatible with pregnancy, with no known teratogenic risk at topical doses, and is one of the few prescription-grade actives that dermatologists routinely continue in pregnant patients. For lactation, the safety profile is similarly reassuring given low systemic absorption, though controlled nursing studies are absent.

Clindamycin Topical in Pregnancy

Clindamycin phosphate, a topical antibiotic used for inflammatory acne, has reassuring safety data in pregnancy. Systemic absorption from topical clindamycin is minimal, and it is not associated with congenital anomalies. It is one of the preferred options for acne management during pregnancy.

Niacinamide in Pregnancy

Niacinamide (vitamin B3) is generally safe in topical use across pregnancy and lactation. No teratogenic signal exists at topical doses. It remains usable as a skin-barrier and anti-inflammatory agent throughout reproductive life stages.

Contraception Requirements

Agency does not prescribe oral isotretinoin (Accutane), which requires enrollment in iPLEDGE with mandatory contraception. However, tretinoin-containing topical formulas carry enough theoretical risk that any woman of reproductive age using them should use reliable contraception if she is not planning pregnancy. This is not a requirement Agency enforces through a formal contraception-verification system, which is a gap compared to office-based prescribing.

What Agency Prescribes: The Formulary in Clinical Context

Agency's custom formulas typically draw from a defined set of actives. The core options include tretinoin (0.01% to 0.1%), niacinamide (2% to 4%), azelaic acid (up to 15%), clindamycin phosphate (1%), and tranexamic acid (2% to 3%) for hyperpigmentation. Some tiers include ivermectin for rosacea.

Tretinoin Efficacy Data

Tretinoin has decades of evidence behind it. A landmark 1995 vehicle-controlled trial in the Journal of the American Academy of Dermatology demonstrated significant reduction in both comedonal and inflammatory lesions at 0.025% and 0.05% concentrations over 12 weeks. The drug also upregulates procollagen synthesis, which has made it the most evidence-backed topical anti-aging compound available.

The dose range Agency uses is clinically appropriate. The titration approach, starting low and increasing based on tolerance, is standard practice.

Tranexamic Acid for Hyperpigmentation

Tranexamic acid is a newer addition to prescription-skincare formularies. It works by inhibiting the interaction between keratinocytes and melanocytes, reducing melanin synthesis. A 2020 systematic review in the Journal of the American Academy of Dermatology found that topical tranexamic acid significantly reduced melasma severity scores compared to placebo, with a favorable safety profile. This is a meaningful option for women with melasma related to oral contraceptive use or pregnancy (chloasma), and Agency's inclusion of it is clinically sound.

The Compounding Question

Some Agency formulas are compounded combinations rather than single FDA-approved products. Compounded drugs are regulated by state pharmacy boards and the FDA under separate rules, and they are not required to demonstrate bioequivalence to approved products. That does not make them unsafe, but it means the exact bioavailability of your specific formula at your specific concentration has not been tested in a clinical trial. This is true of most prescription skincare telehealth platforms, not a unique Agency failing, but it is worth knowing.

Agency vs. Alternative Platforms and Clinical Pathways: A Practical Comparison

The Agency Life-Stage Fit Matrix below is a WomanRx original framework to help you assess whether Agency, a competing platform, or an in-person clinician is the right match for your skin concern and your current life stage.

| Life Stage | Primary Skin Concern | Agency Fit | Better Alternative | |---|---|---|---| | Reproductive years, no hormonal disorder | Acne, texture, early photoaging | Good | Agency or Curology reasonable | | PCOS, androgen-driven acne | Persistent jawline/chin acne | Partial | Add in-person prescriber for spironolactone workup | | Trying to conceive | Acne or hyperpigmentation | Poor for tretinoin | Azelaic acid-only plan; OB-GYN co-management | | Pregnant | Any skin concern | Poor for tretinoin/retinoids | OB-GYN or maternal-fetal medicine dermatology consult | | Breastfeeding | Acne, postpartum melasma | Partial | Azelaic acid and clindamycin; avoid tretinoin | | Perimenopause | Acne plus dryness, texture, laxity | Partial | Consider menopause-trained clinician for hormonal workup | | Post-menopause | Textural aging, hyperpigmentation | Good for tretinoin | Agency reasonable; collagen peptide and estrogen skin data also worth reviewing | | Rosacea | Redness, papulopustular lesions | Moderate | Agency ivermectin option exists; confirm rosacea subtype first |

Is Agency Legit? Assessing the Platform's Clinical Credibility

The short answer is yes, with caveats. Agency employs licensed prescribers, uses a real pharmacy dispensing system, and prescribes drugs with genuine clinical evidence behind them. The concern is not whether the drugs work. Tretinoin works. The concern is whether a skin-photo intake form is sufficient clinical assessment for a drug prescribed to reproductive-age women.

A 2021 review in JAMA Dermatology examining teledermatology quality found that asynchronous store-and-forward models, the category Agency uses, demonstrated diagnostic accuracy comparable to in-person assessment for common dermatologic conditions including acne, but noted limitations in capturing systemic contributors to skin disease. Hormonal drivers are exactly those systemic contributors.

Agency's prescribers are real. Their authority to order labs, however, is not part of the platform's current workflow. That is a structural limit, not a character flaw.

Real-User Experience vs. Clinical Reality

The reviews for Agency are broadly positive for the specific use case of adult acne and texture improvement in otherwise healthy women. Where reviews turn negative, two patterns emerge: skin purging that was not adequately counseled in advance, and acne that returned after initial improvement because the hormonal driver was never addressed.

A tretinoin formula will produce an initial purge in many users, typically peaking at weeks four to six, before improvement becomes visible. Studies show that patient drop-out during the retinoid purge phase is a major reason for perceived treatment failure. Better pre-treatment counseling on this timeline is something in-person dermatology consistently does better than asynchronous telehealth.

Who This Platform Is Right For and Who Should Go Elsewhere

Good candidates for Agency

You are a reasonable candidate for Agency if you are a woman in your twenties to forties with persistent mild-to-moderate acne or uneven skin tone, you are not pregnant or planning pregnancy in the near term, you are using reliable contraception, your skin concern is not associated with new hair loss or menstrual irregularities, and you have already tried or are comfortable coordinating over-the-counter products with a prescription formula.

Who should seek a different or additional care pathway

You need more than Agency can offer if your acne peaks predictably with your cycle in a pattern suggesting PCOS or endometriosis, you are in the perimenopausal transition and noticing simultaneous acne and dryness and mood changes, you are pregnant or actively trying to conceive, you are in the first six months postpartum and breastfeeding, you have new hair thinning alongside facial acne (get DHEAS, total testosterone, and free androgen index checked), or you have tried topical-only approaches for more than six months without durable improvement.

In those cases, Agency may still be part of your skincare, but it should sit alongside an OB-GYN, a reproductive endocrinologist, or a menopause-trained clinician who can look at the hormonal picture, not just the pore.

The Evidence Gap: What Has Not Been Studied in Women

Women have historically been underrepresented in dermatology clinical trials, and telehealth skincare platforms have not yet generated peer-reviewed outcomes data stratified by hormonal status, life stage, or reproductive history. Agency has not published clinical trial data on its own patient population. The tretinoin evidence base is strong, but that evidence was not built on D2C telehealth populations. What works in a controlled trial at a university dermatology department does not automatically translate to a self-managed topical regimen ordered through an app.

This is not an indictment of Agency specifically. It is the honest truth about the evidence base for all prescription skincare telehealth platforms. You deserve to know which parts of your treatment plan are backed by decades of controlled trials and which parts are reasonable extrapolations from that evidence applied to a new delivery model.

How Much Does Agency Cost?

Agency's pricing is approximately $40 to $85 per month for a custom formula, depending on the tier and whether the consultation fee is bundled. That price point is significantly lower than in-person dermatology plus pharmacy costs in most US markets, which makes it accessible for women who lack dermatology coverage.

The cost comparison changes if you need a hormonal workup. A fasting insulin, DHEAS, total testosterone, free androgen index, and LH/FSH panel ordered through your OB-GYN or primary care provider adds cost but delivers clinical information that a prescription skincare platform cannot. If you have been spending $60 a month on Agency formulas for a year without durable results, that lab panel may be the most cost-effective next step.